Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T38360 |
NBC 19
|
||
Potent NLRP3 inflammasome inhibitor (IC50 = 60-80 nM). Inhibits nigericin- and ATP-induced IL-1β release. Baldwin et al (2017) Boron-Based Inhibitors of the NLRP3 Inflammasome. Cell Chem.Biol. 24 1321 PMID:28943355 |Redondo-Castro et al (2018) Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses. Sci.Rep. 8 5667 PMID:29618797 | |||
T9655 |
NBC 6
|
||
NLRP3-IN-NBC6 是一种有效的选择性 NLRP3炎性小体抑制剂 ,IC50为574 nM,其作用独立于 Ca2+。NLRP3-IN-NBC6 抑制 Nigericin 诱导的 THP-1 细胞炎症反应和 Imiquimod 诱导的 LPS-primed 的骨髓源性巨噬细胞 (BMDMs) 释放 IL-1β。 | |||
T2010 |
S0859
|
Others | Others |
S0859 是一种 N-氰基磺酰胺,是选择性高亲和力的 Na+/HCO3-共转运体抑制剂,可逆性地抑制 NBC 介导的细胞内 pH (pHi) 恢复,Ki 为1.7 μM。 | |||
T79410 | anti-TNBC agent-3 | ||
Anti-TNBC agent-3 (compound 3g) 作为凋亡诱导剂,展现了抗增殖活性针对癌细胞。在三阴性乳腺癌(TNBC)异种移植模型上,该化合物有效地抑制了肿瘤生长及其转移。 | |||
T79311 |
CNBCA
|
||
CNBCA是一种有效的SHP2酶抑制剂,具有选择性和竞争性,IC50值为0.87 μM。该化合物可结合SHP2全长蛋白并抑制其酶活性,进而阻止Akt和ERK1/2的磷酸化,以及抑制BT474和MDA-MB468乳腺癌细胞的生长。CNBCA主要用于乳腺癌的研究。 | |||
T39815 | anti-TNBC agent-1 | ||
anti-TNBC agent-1 is a highly effective compound specifically designed to target and combat triple-negative breast cancer (TNBC). It demonstrates remarkable potency against various breast cancer cell types, with IC50 values spanning from 0.20 μM to 0.27 μM. The mechanism of action of anti-TNBC agent-1 involves inducing apoptosis in SUM-159 cells through the mitochondria pathway, as well as causing G1 phase arrest in these cells. | |||
T79699 | anti-TNBC agent-2 | Apoptosis | Apoptosis |
Anti-TNBC agent-2(3j)是一款针对三阴性乳腺癌(TNBC)的嘌呤衍生化合物。它能够引导MDA-MB-231细胞走向凋亡(apoptosis),阻碍其迁移和血管生成能力,并在TNBC异种移植模型中,抑制肿瘤生长与转移,同时下调Ki67和CD31蛋白的表达水平。Anti-TNBC agent-2主要用于三阴性乳腺癌的科研领域。 |